From:  Analysis of the benefit of anti-PD-1 monotherapy according to NGS-diagnosed genetic alterations in patients with non-small cell lung cancer

Baseline characteristics of patients with non-small-cell lung cancer treated with immune checkpoint inhibitors

VariableWhole cohort (n = 107)
Sex
        Male70 (65%)
        Female37 (35%)
Age
        Median65
        IQR[59; 73]
Smoking status
        Non-smoker9 (8%)
        Smoker97 (91%)
        Unknown1 (1%)
Histology
        Adenocarcinoma96 (90%)
        Squamous8 (7%)
        Undifferentiated2 (1.9%)
        Large cell carcinoma1 (0.9%)
Line of treatment
        133 (31%)
        257 (53%)
        ≥ 317 (16%)
PD-L1 TPS
        0%14 (13%)
        1–49%23 (21%)
        > 50%44 (41%)
        Missing26 (24%)
Return to article view

PD-L1: programmed death ligand 1; ICR: confidence interval range; TPS: tumor proportion score